Login to Your Account

Pharma: Other News To Note

Wednesday, July 31, 2013
• Novartis AG, of Basel, Switzerland, disclosed that a patient taking the oral multiple sclerosis pill Gilenya (fingolimod) developed potentially fatal viral disease progressive multifocal leukoencephalopathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription